Insight journal - Technology

Antibiotics partnering analysis in biopharma industry

Posted on 02 June 2014

Tags: , , ,

The  last two years alone has seen $1.9 billion spent on antibiotics partnering by the biopharma industry.

Antibiotics partnering has seen an increase in partnering after 2009 gaining momentum since 2011. Last year saw 51 partnering deals announced in the antibiotics market.

Figure 1: Antibiotics partnering by year - 2009-2014

Anti1

 

 

 

 

 

 

Source: Current Agreements, 2014

Not all big pharma and big biotech companies are actively involved in antibiotics partnering, however companies such as GlaxoSmithKline with 9 deals and Astellas with 7 deals signed since 2009, are particularly active in this area.

Figure 2: The most active dealmakers in antibiotics technology biopharma industry 2009-2014

anti2

 

 

 

 

 

 

Source: Current Agreements, 2014

When analyzing individual antibiotic classes , data reveals that popular areas for partnering are penicillin and cephalosporin types.

Figure 3: Antibiotics partnering by technology type in biopharma industry since 2009

anti3

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

According to the Current Agreements life science deals and alliance database, antibiotics partnering commonly takes place for the infectives therapeutic area with 181 deals signed since 2009.

Figure 4: Antibiotics partnering by disease type in biopharma industry since 2009

anti4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

The following figure shows the leading antibiotics deals by headline value of the deal when announced between 2009 and April 2014.

Figure 5: Antibiotics partnering by deal value  in biopharma industry - 2009-2014

 

anti5

 

 

 

 

 

 

Source: Antibiotics Partnering Terms and Agreements report, 2014

The  Antibiotics Partnering Terms and Agreements report published by Current Partnering provides full details of over 140 antibiotics partnering deals announced since 2008 and includes average deal terms including headline, upfront, milestone and royalty rates, where available. In addition, the report provides details of deals broken down by deal type, stage of development, company A-Z and technology type. More details here

Sources

The above information has been abstracted from the following resources:

Shamini Thiagarajan

 

Related

Read: more antibiotics deals in pharma, biotech, life science partnering deal news, insights and glossary

ReportAntibiotics Partnering Terms and Agreements

View also: Other technology type reports

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply